Loading
Life sciences · Journal article
BMC Infectious Diseases · September 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Mycoplasma pneumoniae is a leading cause of community-acquired pneumonia worldwide. Due to intrinsic beta-lactam resistance, macrolides are recommended as first-line treatment. However, macrolide-resistant M. pneumoniae (MRMP) has been increasingly reported globally, particularly in Asia, necessitating updated data to understand current trends. A time-limited paediatric surveillance programme was implemented in 2024 to elucidate the epidemiology and clinical impact of MRMP in Singapore. From Jan–Apr 2024, paediatric M. pneumoniae -positive samples from hospitals and the community acute respiratory infection (ARI) surveillance programme were tested at Singapore’s National Public Health Laboratory for genotypic macrolide resistance. Demographic, clinical, and epidemiological data were reviewed for hospitalised cases. Statistical analysis was performed to assess characteristics associated with macrolide resistance. A total of 412 M. pneumoniae cases (275 hospitalised and 137 community cases, aged 0–16 years) were successfully genotyped and included in the analysis. Of these, 16.7% (95% CI 12.5–21.7%) and 19.7% (95% CI 13.4–27.4%) of hospitalised and community cases, respectively, possessed the A2063G point mutation for macrolide resistance. No differences in age, ethnicity, comorbidities, symptomatology, presence of co-infections, care acuity, or mortality rate were detected between hospitalised MRMP and macrolide-susceptible M. pneumoniae cases. In adjusted analyses, MRMP cases had higher likelihood of recent overseas travel (OR 2.28, 95% CI 1.09–4.77), and longer duration of fever (mean difference 2.24 days, p < 0.01) and hospitalisation (mean difference 0.94 days, p = 0.01). All MRMP inpatients were discharged well. MRMP prevalence was 16.7% among hospitalised paediatric cases and 19.7% among community cases. MRMP was associated with longer fever duration and hospitalisation, but no other evidence of greater disease severity was observed. The findings do not indicate an immediate need to alter current local empirical treatment recommendations, although further research is needed to evaluate treatment effectiveness in MRMP. Periodic surveillance and responsible antimicrobial stewardship are crucial in mitigating rising resistance.